Study #2021-0619
A first-in-human phase 1 trial of T-Cell membrane-anchored tumor targeted Il12 (Attil12)- T-Cell therapy in subjects with advanced/metastatic soft tissue and bone sarcoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, attIL2-T cells
Description
To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Soft Tissue Sarcoma, Bone Sarcoma
Study phase:
Phase I
Physician name:
John Livingston
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.